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315* Cardiac autonomic neuropathy (CAN) is more likely to occur in
cystic ﬁbrosis (CF) patients with or without diabetes than in
patients with type 1 diabetes (T1DM)
R. Rashid1, A.A. Tahrani2, M. Piya2, N. Edward1, D. Honeybourne1, M. Newnham3,
M.J. Stevens2, J. Whitehouse1. 1Heart of England NHS Trust, Respiratory and CF,
Birmingham, United Kingdom; 2Heart of England NHS Trust, Diabetes, Birmingham,
United Kingdom; 3Heart of England NHS Trust, Birmingham, United Kingdom
Background: We have previously demonstrated that there is a high prevalence of CAN
in CF patients with and without CF related diabetes (CFRD). In order to determine
whether CF augments the toxic effect of glucose on the autonomic nervous system, we
have compared CF patients with non-CF patients with Type 1 diabetes (T1DM).
Aim: To compare the prevalence and severity of CAN in CFRD, CF without diabetes
and T1DM.
Methods: A prospective study was carried out at Heartlands Hospital where CF
patients with and without CFRD and T1DM patients were recruited. CAN was assessed
using heart rate variability and spectral analysis during timed deep breathing, Valsalva
manoeuvre, standing and postural blood pressure change using ANSAR 3.0 (The Ansar
group inc, Pennsylvania) CAN was diagnosed when 2 or more standardised tests were
abnormal. The severity of CAN was assessed by spectral analysis.
Results: See the table.
CF without DM CFRD T1DM p value
(CFRD versus T1DM)
Male gender, % 33 31 60
Age 22 28 35 <0.001
HbA1c 5.75 7.13 7.99 <0.001
Prevalence of CAN, % 22 38 11 0.046
Summary and Conclusions: The prevalence of CAN is higher in CFRD patients with
compared with patients with T1DM, despite the fact that the T1DM group were older
and had higher HbA1c. Severity of CAN was signiﬁcantly higher in CFRD compared
with T1DM in various sympathetic and parasympathetic parameters (p values ranging
from 0.006–0.000). We conclude that CF increases the toxic effect of glucose on the
autonomic nervous system. Although the mechanism of this effect is unclear, chronic
inﬂammatory mechanisms are likely to contribute to this ﬁnding.
316* Cardiac autonomic neuropathy (CAN) is related to lung function
in adults with cystic ﬁbrosis related diabetes (CFRD)
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Background: CAN is a well recognised complication of diabetes mellitus and is
associated with higher levels of systemic inﬂammation and increased cardiovascular
risk. We have previously demonstrated a high prevalence of CAN in patients with
and without CFRD. The aim of this study was to assess the relationship between
lung function and CAN in CFRD.
Methods: We performed a prospective cross sectional study of adults with CF
adults. Demographic data including, biochemistry, spirometry, presence of CF
liver and pancreatic disease and HbA1c were recorded. CAN was assessed using
heart rate variability and spectral analysis during baseline, deep breathing, valsalva
manoeuvre, standing position and postural blood pressure change using ANSAR 3.0
(Ansar group Inc., Pennsylvania). A diagnosis of CAN was made on the basis of 2
abnormal standardised tests.
Results: 29 subjects with CFRD were recruited (31% male, mean age 27). The
prevalence of CAN was 38% in CFRD patients. There was a trend towards lower
FEV1 in CAN+ compared with CAN− patients [median (IQR) 1.4 L (1.1−1.7) vs
1.7 L (1.3−2.2), p = 0.26]. FVC was lower in CAN+ compared with CAN− patients:
2.4 L (1.6−2.7) vs 3.0 L (2.2−3.5), p = 0.11. There were several positive (statistically
signiﬁcant) correlations between spectral analysis indices, FEV1 and FVC. No
association between pancreatic status, presence of liver disease, vitamin D or E
levels or HbA1c between patients with and without CAN was found.
Conclusion: Severity of lung function impairment was positively associated with
the presence of CAN. We hypothesise that this ﬁnding could be due to increasing
levels of systemic inﬂammation as CF lung disease progresses.
317 Service provision for cystic ﬁbrosis related diabetes (CFRD) in
UK CF centres
J. Daniels1, P. Dyce1, C. Cowperthwaite1, M.J. Walshaw1. 1Liverpool Heart and
Chest Hospital, Amanda unit, Liverpool, United Kingdom
Introduction: CFRD is associated with clinical deterioration and signiﬁcant com-
plications, and is increasingly common as patients live longer. Because management
is different from traditional diabetes, specialist care is needed to achieve optimum
outcomes. We were interested in how different CF clinics in the UK managed
CFRD care.
Method: Using a structured questionnaire we surveyed 15 CF centres in the
UK (total 1513 patients) asking the proportion with CFRD, who led CFRD care,
frequency of reviews, treatments used, annual screen content and satisfaction with
service.
Results: There were 6 adult (1047 patients, 327 (31%) with CFRD), 7 paediatric
(381 patients, 9 (1%) with CFRD) and 2 mixed (85 patients, 11 (13%) with CFRD)
centres. Care was led by diabetes nurse specialists in 6 centres, shared between
disciplines in 8, and led by a CF nurse specialist (CFNS) in 1. Annual CFRD screens
were performed in all centres and were based on all elements of NICE diabetes
guidelines in 8, partially in 4, and less in the remainder. Treatment of complications
were shared between disciplines in every centre. All used insulin therapy, 9 used
oral glycaemic agents at times and 3 insulin pumps. CFNS instigated insulin in 2
centres, in a further 3 in conjunction with medical staff, but in the remainder it was
done by CF clinicians or endocrinologists. 13 centres (87%) were satisﬁed with the
provision of their service.
Conclusion: There is a wide variation of care provided for CFRD. In some centres
CFNS were pivotal, in others care was outsourced to other specialities. More insight
is needed into the most appropriate way of delivering care for these complex
patients.
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C.M. Ohri1, K. Marwa1, E. Glennon1, E.F. Nash1, J. Whitehouse1, M.J. Stevens2,
D. Honeybourne1. 1West Midlands Adult Cystic Fibrosis Centre, Birmingham
Heartlands Hospital, Birmingham, United Kingdom; 2Department of Diabetes &
Endocrinology, Birmingham Heartlands Hospital, Birmingham, United Kingdom
Background: The prevalence of cystic ﬁbrosis (CF)-related diabetes mellitus
(CFRD) is increasing, reﬂecting the improvements in management of CF itself.
As a result, a diabetes specialist nurse with an interest in CFRD (CFDSN) was
appointed to our CF multidisciplinary team in February 2008. The aim of this
study was to assess the impact that this has made to the control of diabetes in
patients with CFRD at our regional adult CF centre.
Methods: We conducted a retrospective cohort study including all patients with
CFRD attending our centre between 2006 and 2010. We obtained lung function
and BMI for all patients. We compared HbA1C in 2006 to the HbA1C in 2010.
We also analysed the results of a patient satisfaction questionnaire completed by
20 patients in 2010.
Results: Table 1 compares data from 2006 (prior to the CFDSN) and 2010 (2 years
after our CFDSN was appointed). Median HbA1C signiﬁcantly improved from 2006
to 2010 (p< 0.02). All 20 patients felt that their knowledge of CFRD improved
following contact with our CFDSN. Prior to her appointment, 8/20 patients felt that
they did not have easy access to a Diabetes Specialist Nurse.
Discussion: This study shows that the glycaemic control of our cohort of patients
with CFRD has improved since the appointment of a CFDSN. Patients in particular
report an improved access to specialist diabetes advice which has helped to improve
their knowledge. The observed improvements in outcomes may be confounded by
other factors, but we feel that a CFDSN can play a vital role in the management
of patients with CFRD.
Table 1
Year CF patients BMI HbA1C On insulin
Total CFRD patients Median IQR Median IQR
2006 328 90 (27.4%) 22.7 20.9–24.7 7.2% 6.2−8.4% 86 (95.6%)
2010 339 142 (41.9%) 22.7 20.7–24.4 6.7% 6−7.5% 138 (97.2%)
